The IMCAS World Congress, aesthetic medicine's biggest annual gathering, ran January 30 to February 1 at the Palais des Congrès de Paris: some 20,000 attendees from 140 countries, around a thousand speakers, and more than 370 exhibitors across four levels, with roughly 344 hours of sessions. Retail to See reads this congress the way a merchandiser should read a patent filing, because what aesthetic medicine debates in Paris in winter tends to arrive on the beauty shelf, translated and diluted, within a couple of years.
Three storylines from this edition matter well beyond the clinic.
Exosomes are the next ingredient story
The scientific programming kept circling exosomes, the cell-derived vesicles being explored for wound healing, hair growth, and scar remodeling. The regulatory picture is unsettled and the sessions said so plainly. But the industry is not waiting: Dermalogica used the congress to show an exosome booster built on bacterial-derived, non-human exosomes, exactly the kind of regulatory-friendly workaround that lets a clinical buzzword cross into cosmetics. Prollenium, a filler company, announced a strategic pivot toward skin rejuvenation built on polynucleotides, exosome-based approaches, and collagen biostimulants.
Translation for retail: "exosome" is about to become a shelf word, the way "peptide" and "growth factor" did before it. The gap between what the clinical data supports and what the packaging will imply is where the category's next credibility fight starts.
The GLP-1 face is now an aesthetics category
The congress gave serious programming time to the aesthetic consequences of GLP-1 weight-loss drugs: the facial volume loss, the accelerated-aging look that rapid fat loss produces. Practitioners are building combination protocols around it.
Beauty retail should be paying closer attention to this than it is. A pharmacological wave that changes how millions of faces and bodies look creates demand that does not stop at the clinic door: firming claims, volume-and-elasticity positioning, body care for changed skin. The consumer the aesthetics industry calls a patient on Monday is the same person standing at a beauty counter on Saturday.
From filling to quality, officially
The broader scientific arc was the move away from volumization toward skin quality: polynucleotides and PDRN, biostimulators, and a new frankness about the overfilled look, which now has its own name in the literature. Add the rise of "prejuvenation," earlier and lighter intervention, and the direction is clear. Aesthetics is converging on the same promise consumer skincare sells, better tissue rather than disguised aging, from the opposite side.
The industry news backed the science. Galderma presented late-stage data on a liquid neurotoxin with onset from day one and duration past six months, Allergan Aesthetics launched a global patient-experience program, and Teoxane marked ten years of its resilient hyaluronic-acid technology. These companies are building consumer-facing brand machinery, not just clinical pipelines, and the boundary with beauty marketing thins every year.
Why it matters
Salmon-DNA serums and longevity actives are already reaching trade-show floors and early retail shelves, and every one of those stories was an IMCAS session before it was a product. This congress said the next arrivals are exosomes, GLP-1-adjacent skincare, and quality-over-volume language. The retailers who learn the vocabulary now will recognize the pitch when it walks into their buying meetings. The ones who do not will be told it is revolutionary, and will have no way to know better.
